Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ: XERS · Real-Time Price · USD

Compare

7.36

0.00 (0.00%)

At close: Feb 2, 2026, 4:00 PM EST

7.57

+0.21 (2.82%)

After-hours: Feb 2, 2026, 7:40 PM EST

Xeris Biopharma Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	266.14	203.07	163.91	110.25	49.59	20.44
Revenue Growth (YoY)	42.05%	23.89%	48.68%	122.32%	142.67%	650.74%
Cost of Revenue	41.1	36.83	28.65	22.63	13.32	9.33
Gross Profit	225.04	166.24	135.27	87.61	36.27	11.11
Selling, General & Admin	168.91	157.38	146.1	137.75	116.06	73.73
Research & Development	29.38	25.56	22.34	20.97	25.16	18.92
Amortization of Goodwill & Intangibles	10.84	10.84	10.84	10.84	0.55	-
Operating Expenses	209.14	193.78	179.28	169.55	141.77	92.65
Operating Income	15.9	-27.55	-44.01	-81.94	-105.5	-81.55
Interest Expense	-29.63	-30.49	-26.61	-14.1	-7.18	-10.66
Interest & Investment Income	4.19	5.32	4.75	2.58	0.73	1.47
Other Non Operating Income (Expenses)	0	0.01	0	1.76	-0.7	-0.01
EBT Excluding Unusual Items	-9.54	-52.7	-65.87	-91.7	-112.66	-90.75
Merger & Restructuring Charges	-	-	-	-	-9.66	-2
Gain (Loss) on Sale of Investments	-	-	-	-	-0.41	-
Legal Settlements	-	-	-	-	-	1.5
Other Unusual Items	-6.1	-4.4	2.36	-4.38	-	-
Pretax Income	-15.64	-57.1	-63.5	-96.08	-122.73	-91.25
Income Tax Expense	-	-2.27	-1.25	-1.42	-	-0.11
Net Income	-15.64	-54.84	-62.26	-94.66	-122.73	-91.14
Net Income to Common	-15.64	-54.84	-62.26	-94.66	-122.73	-91.14
Shares Outstanding (Basic)	156	147	138	136	79	43
Shares Outstanding (Diluted)	156	147	138	136	79	43
Shares Change (YoY)	8.48%	6.61%	1.51%	71.62%	85.32%	63.32%
EPS (Basic)	-0.10	-0.37	-0.45	-0.70	-1.55	-2.14
EPS (Diluted)	-0.10	-0.37	-0.45	-0.70	-1.55	-2.14
Free Cash Flow	9.98	-37.85	-49.29	-103.42	-96.62	-80.94
Free Cash Flow Per Share	0.06	-0.26	-0.36	-0.76	-1.22	-1.90
Gross Margin	84.56%	81.86%	82.52%	79.47%	73.14%	54.35%
Operating Margin	5.97%	-13.56%	-26.85%	-74.32%	-212.74%	-399.05%
Profit Margin	-5.88%	-27.00%	-37.98%	-85.86%	-247.48%	-446.00%
Free Cash Flow Margin	3.75%	-18.64%	-30.07%	-93.80%	-194.84%	-396.06%
EBITDA	28.04	-15.48	-31.68	-69.7	-103.62	-80.08
EBITDA Margin	10.53%	-7.62%	-19.33%	-63.22%	-208.95%	-
D&A For EBITDA	12.13	12.07	12.33	12.24	1.88	1.47
EBIT	15.9	-27.55	-44.01	-81.94	-105.5	-81.55
EBIT Margin	5.97%	-13.56%	-26.85%	-74.32%	-212.74%	-
Revenue as Reported	266.14	203.07	163.91	110.25	49.59	20.44

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q